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Abstract
CDC designated category A infectious agents pose a major risk to national security and
require special action for public health preparedness. They include viruses that cause viral
hemorrhagic fever (VHF) syndrome as well as variola virus, the agent of smallpox. VHF is
characterized by hemorrhage and fever with multi-organ failure leading to high morbidity
and mortality. Smallpox, a prior scourge, has been eradicated for decades, making it a par-
ticularly serious threat if released nefariously in the essentially non-immune world popula-
tion. Early detection of the causative agents, and the ability to distinguish them from other
pathogens, is essential to contain outbreaks, implement proper control measures, and pre-
vent morbidity and mortality. We have developed a multiplex detection assay that uses sev-
eral species-specific PCR primers to generate amplicons from multiple pathogens; these
are then targeted in a ligase detection reaction (LDR). The resultant fluorescently-labeled
ligation products are detected on a universal array enabling simultaneous identification of
the pathogens. The assay was evaluated on 32 different isolates associated with VHF
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(ebolavirus, marburgvirus, Crimean Congo hemorrhagic fever virus, Lassa fever virus, Rift
Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vac-
cinia virus (the agent of smallpox and its vaccine strain, respectively). The assay was able
to detect all viruses tested, including 8 sequences representative of different variola virus
strains from the CDC repository. It does not cross react with other emerging zoonoses such
as monkeypox virus or cowpox virus, or six flaviviruses tested (St. Louis encephalitis virus,
Murray Valley encephalitis virus, Powassan virus, Tick-borne encephalitis virus, West Nile
virus and Japanese encephalitis virus).
Introduction
Viral hemorrhagic fever is a febrile syndrome associated with vascular damage caused by RNA
viruses of the families: Filoviridae [Ebolavirus andMarburgvirus], Arenaviridae [Lassa fever
virus (LASV)], Bunyaviridae [Rift Valley fever virus (RVFV) and Crimean Congo hemorrhagic
fever virus (CCHFV)], and Flaviviridae [Yellow fever virus (YFV), and dengue virus (DENV)].
Most are zoonotic, vector-borne, and may cause sporadic, unanticipated, and devastating out-
breaks in endemic areas [1]. The Center for Disease Control and Prevention (CDC) has desig-
nated Filoviridae and Arenaviridae as Category A due to their ease of transmission, high
mortality, risk to national security, and potential for causing public panic and social disruption.
Many agents of VHF are designated as emerging or reemerging pathogens and threaten not
only their traditional areas of endemicity in developing countries but new territory in other
countries as well [2–5]. There are few preventative vaccines, and clinical management is largely
supportive due to the paucity of effective chemotherapeutic agents. The case fatality ratio for
outbreaks of the filoviruses in Africa has ranged from approximately 36–90% and 83–90% for
Marburg and Ebola, respectively [6–8]. Furthermore, the infection of skilled and traditional
healers tending the sick complicates care and control measures while abetting nosocomial
transmission and the spread of disease [2, 9, 10]. The 2014 West African Ebola outbreak,
which is the largest recorded thus far, exemplifies these difficult infection control issues [11–
13]. The filoviruses, CCHFV, and LASV require the highest level of laboratory containment
(containment level 4 or biosafety level 4), however, few such facilities are present in resource-
poor endemic countries [2]. The worldwide threat of VHF agents to the public health, as well
as to veterinary and agricultural communities, is increasingly recognized, as is the possibility of
the accidental or malicious release of some of these viruses as agents of bioterror [14, 15].
Human smallpox was eradicated over 30 years ago. Since then, vaccination to poxviruses
has largely stopped, leading to a worldwide population of susceptible individuals [14, 16]. Vari-
ola virus is legally retained at only two World Health Organization (WHO) Collaborating Cen-
ter repositories. Reports of covert, undeclared stocks and weaponized virus have fueled fears
that variola may be reintroduced as a bioterror agent, an issue of continuing national and inter-
national concern [17–19].
Recognition of index cases with the exotic and geographically restricted VHF viruses, or
eradicated smallpox, depends upon the clinical suspicion and diagnostic acumen of first-line
physicians [20, 21]. VHF infections due to endemic natural outbreaks, infection in returning
travelers, or suspected acts of bioterrorism continue to challenge public health and clinical lab-
oratories. Effective infection control and the implementation of public health containment
plans require rapid and effective diagnostic tests. [1, 22].
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Rapid detection and specific pathogen identification are key to the control of outbreaks due
to VHF and variola viruses. In addition, rapid screening of a large number of samples can be
anticipated as was the case in the 2001 anthrax outbreak [15]. There are several molecular
detection assays that have been developed for rapid detection of VHF viruses, the majority of
which are based on real-time PCR [23–26]. These assays have improved the sensitivity and the
turn-around time for detection of VHF, while significantly reducing the biohazard potential of
cultivating these organisms in the laboratory. However, real-time PCR assays often have lim-
ited multiplexing capabilities and require several assays to be run for detection of multiple etio-
logic agents [15, 27]. An additional concern is mutation in these viruses resulting in the
alteration of protein sequences and targets used for molecular detection. Sequencing has estab-
lished that in the recent West African Ebola outbreak, isolates from Sierra Leone had genomes
that varied from PCR probes used for four separate assays used for EBOV and pan-filoviral
diagnostics [19]. Mutations could potentially impact diagnosis due to mismatch between target
and primer/probe, not only in current assays, but also in those that are in the process of being
released [19, 28, 29].
Multiplex detection of several viruses using real-time PCR strategy is limited by the choice
of fluorescent dyes and their spectral overlap [30, 31]. Palacios et al. have described a multiplex
assay for detecting VHF viruses that utilizes PCR primers containing unique mass tags that are
then detected by a mass spectrometer [24]. A comprehensive molecular detection panel for
high-throughput identification of these viruses, using a single cycling protocol and fluorescent
technology, would be a useful addition to current techniques available for molecular identifica-
tion of these pathogens [27, 32, 33]. PCR/LDR is a versatile technique that has been used in the
detection of pathogens in clinical as well as environmental samples [34–36]. We have previ-
ously reported a PCR/LDR universal array-based technique for the simultaneous detection and
identification of all four serotypes of DENV and West Nile virus from serum and plasma sam-
ples as well as from mosquito pools [37, 38]. Here we describe use of this technology for the
multiplex detection and identification of seven VHF viruses (ebolavirus [Zaire, Sudan and Res-
ton ebolaviruses], MARV, LASV, CCHFV, RVFV, YFV, DENV) and two orthopoxviruses
[variola virus (VARV) and vaccinia virus (VACV)] in a single assay.
Methods
Ethics Statement
This study was performed in accordance with a protocol approved by the Institutional Review
Board of the Weill Medical College of Cornell University.
Viral Isolates
Vaccine strains of RVFV (MP12) and YFV (17D) were kindly provided as a gift by Dr. Robert
Tesh, University of Texas Medical Branch, Galveston, TX. Inactivated viral culture superna-
tants of ebolavirus [Zaire virus (EBOV), Sudan virus (SUDV), and Reston virus (RESTV)]
(n = 4), MARV (n = 3), CCHFV (n = 3), RVFV (n = 1) and LASV (n = 1) were obtained from
the United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Mary-
land. Genomic DNA from VACV virus (n = 6) was obtained from NIH Biodefense and Emerg-
ing Infections Research Resources Repository, NIAID, NIH. The two target amplicons of
VARV [amplicon 1 (RAP94): 421bp; nt: 77,877–78,298 and amplicon 2 (RPO147): 485bp; nt:
82,372–82,856] representing all VARV sequence variants for these genetic regions [39] were
obtained from the CDC Poxvirus and Rabies Branch, Centers for Disease Control and Preven-
tion, Atlanta, GA with the permission of the WHO and in accordance with all applicable
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regulations [40]. Details of viral cultures and nucleic acid used in the study are provided in
Tables 1 and 2.
As previously described, culture supernatants from standard isolates of the four serotypes of
DENV were employed [37]. The following viruses or nucleic acids were used as controls: DNA
from cowpox and monkeypox viruses obtained from ATCC; St. Louis encephalitis virus (strain
MSI-7), Murray Valley Encephalitis virus (strain OR2), Powassan virus (strain M11665), Tick-
borne encephalitis virus (strain K23), West Nile virus (NAT-positive plasma samples from
blood donors) and Japanese encephalitis virus (strain SA-14-14-2) [38].
Oligonucleotide Design
Virus-specific primers were designed as described previously [37, 38]. Briefly, after alignment
of the sequences, areas with relative conservation among different virus strains were chosen for
each virus group and, where possible, for several viral groups (Filoviridae, Flaviviridae and Pox-
viridae) so as to achieve maximum strain coverage with the least number of primers. Primer
sets were designed to simultaneously amplify two different regions in each virus or viral group:
NP and L genes of ebolaviruses (EBOV, SUDV and RESTV) and MARV, S segment of
CCHFV,M and S segments of RVFV, L segment of LASV, NS5 regions of DEN and YF, and
Table 1. Details of viral cultures and nucleic acids used in the study: RNA viruses.
Viral isolate /
Strain
Source/Year Geographic Location Accession Number
Ebolavirus
Zaire ebolavirus’95 Human/1995 Democratic Republic of
Congo
JQ352763
Zaire ebolavirus’76 Human/1976 Democratic Republic of
Congo
NC_002549
Reston ebolavirus Primate/1989 USA NC_004161
Sudan ebolavirus Human/1976 Sudan AF173836*
Crimean Congo hemorrhagic fever
Hy-13 Hyalomma asiaticum tick/1968 China AY900145
UG3010 Human/1956 Democratic Republic of
Congo
AY900143
ArD8194 H. truncatum/1969 Senegal DQ211626
Marburg virus
Musoke Human/1980 Kenya M92834
RAVN Human/1987 Kenya EF490232
Ci67 Human/1967 Germany EF446132
Rift Valley fever virus
ZH501 Human/1977 Egypt DQ380200.
MP-12 Vaccine strain - Z30318
Yellow fever virus
17D Vaccine strain - NC_002031
Dengue virus
DENV-1,-2,-3,-4 Hawaii, New Guinea C, Philippines H87, Philippines
H241
Standard strains KM204119, KM204118, AJ320521,
FJ439174
Lassa virus
Lassa-Jossiah Human/1976 Sierra Leone NC_004297
* The exact sequence of the stock used is not known. The GenBank sequence of the parent strain is indicated.
doi:10.1371/journal.pone.0138484.t001
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the RNA pol (RAP94 and RPO147) genes of VACV and VARV; a total of 57 primers. The
amplicons were ~500 bp in length (range 399–685 bp). The primer sequences contained no
more than three degenerate positions and had a melting temperature of around 72–75°C (S1
Table) [37, 38].
LDR primers were chosen in two to three different conserved regions within each of the two
PCR amplicons for the different virus groups. The primers were designed with the intent of
achieving the highest possible strain coverage in all the different viruses as well as to differen-
tially identify them individually. A total of 250 LDR primers were designed, with melting tem-
peratures between 75 and 80°C; degenerate bases (no more than three in each primer) were
introduced, where required, to account for sequence variations. A complete list of all LDR
primers is provided in S2 Table. The PCR and LDR primers were obtained from Integrated
DNA Technology, Coralville, IA.
The PCR and LDR primers for each of the target regions for all the virus groups were evalu-
ated in separate assays individually. This was performed to evaluate satisfactory signal detec-
tion from each of the regions selected. Primers that failed to produce either PCR amplicon or
generated less than two LDR products were replaced, and new primers were designed. The
LDR primers were designed such that they were able to differentiate between the three species
of ebolavirus tested (EBOV, SUDV and RESTV). The poxvirus primers were designed such
that they were able to discriminate between VARV and VACV and would not cross-react or
produce false positive signals with other Orthopoxvirus species (cowpox and monkeypox
viruses). The flavivirus primers were designed to identify and distinguish DENV and YFV
without cross-reactivity with a panel of flaviruses.
Table 2. Details of viral cultures and nucleic acids used in the study: DNA viruses.
Viral isolate / Strain Source/Year Geographic Location Accession Number
Variola virus PCR amplicons†
BSH75_banu Human/1975 Bangladesh DQ437581
BSH74_nur Human/1974 Bangladesh DQ441420
BSH74_sol Human/1974 Bangladesh DQ441421
BSH74_shz Human/1974 Bangladesh DQ441422
CHN48_horn Human/ 1948 China DQ437582
GER58_hdlg Human/1958 Heidelberg, Germany DQ437584
V73-175 Human/1973 Nepal DQ437588
SAF65_102 Human/1965 Natal, South Africa DQ441435
Vaccinia virus DNA‡
Lister (Elstree) BEI Resources (ATCC) AY678276
Modiﬁed Vaccinia Ankara BEI Resources (ATCC) U94848
Lederle-Chorioallantoic BEI Resources (ATCC) AM501482
New York City Board of Health (NYCBH) Wyeth, calf adapted BEI Resources (ATCC) JN654986
Western Reserve (WR) NIAID,Tissue culture adapted BEI Resources (ATCC) AY243312
International Health Division (IHD) BEI Resources (ATCC) KC201194
†PCR amplicons from RAP94 and RPO147 gene segments (421 and 485 bp respectively) were obtained from the Poxvirus Program, Centers for Disease
Control and Prevention, Atlanta, GA. See text and reference [39] for further details about the VAR strains used for PCR ampliﬁcation.
‡Complete information about the VACV virus DNA is available at the ATCC’s Biodefense and Emerging Infections Research Resources Repository (BEI)
website at http://www.beiresources.org/Catalog/tabid/248/Default.aspx.
doi:10.1371/journal.pone.0138484.t002
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Nucleic Acid Preparation and PCR/LDR Assay
Nucleic acid extraction and one-step RT-PCR amplification (OneStep RT-PCR kit; Qiagen,
Valencia, CA), ligase detection reaction (LDR), and universal array were performed as
described previously [37, 38], with the exception that one-step RT-PCR was performed in a
25 μl final volume using 5 μl of template RNA or DNA. Fig 1 explains the PCR/LDR assay
design and detection protocol. To provide a certain degree of redundancy two regions of each
virus were amplified, and primers for the subsequent ligation reaction were designed targeting
2 or 3 areas within each PCR amplicon. Consequently, up to six ligation products (only 5 liga-
tion products in the case of VARV and VACV) can be generated for each virus to be detected.
However, not all ligation products are required to be present to unambiguously detect and
identify each of the viruses. The presence of any 2 ligation products for a given virus, either two
ligation products from a single PCR amplicon or at least one ligation product from each of the
two amplicons, was considered sufficient for identification. Ligation products bear zip-code
sequences and were detected by hybridization to a universal array bearing complementary zip-
codes. A signal was considered positive for ligation if the intensity of the corresponding zip-
code spot was at least 10-fold higher than the overall average background intensity of the array
as determined by the ScanArray Express v 4.0 (Perkin Elmer, MA). No-template controls pro-
vided no PCR amplicons and consequently no positive signals for any ligation products.
The analyses were repeated in at least 2 different experiments with the exception of Sudan
ebolavirus for which there is a single experiment. We included the following geographic and
genotypic variants: four different strains of three species of ebolavirus (SUDV, RESTV,
EBOV); standard strains of DENV serotypes 1–4; VARV (8 genotypically variant isolates of
V.major virus); and CCHFV (3 isolates; Hy-13 from China, and UG3010 and ArD8194 from
the Democratic Republic of the Congo and Senegal, respectively).
Preparation of RNA Standards for Determination of LOD
Synthetic RNA fragments of the viruses were prepared for LASV, RVFV, and YFV, MARV and
CCHFV [24]. The target regions of LASV, RVFV and YFV viruses to be detected were ampli-
fied by RT-PCR, purified using QIAquick PCR purification kit (Qiagen, Inc., Valencia, CA),
and cloned into the expression vector pGEM T Easy (Promega, Madison, WI) containing the
T7 promoter region. The plasmids were purified, and the presence of complete inserts was con-
firmed by sequencing the inserts using vector-specific primers. Target regions for MAR and
CCHF were synthetically constructed and inserted into the pIDT Blue vector (Integrated DNA
Technologies Coralville, IA). The complete inserts of the target regions thus generated were lin-
earized and in vitro transcribed using the mMessage in vitro transcription kit (Ambion, Austin,
TX). Following DNAse treatment, the synthetic RNA was purified using an RNeasy column
(Qiagen, Inc., Valencia, CA). The quantity of RNA generated for each transcript was deter-
mined using the Ribogreen1 RNA Quantitation Kit (Molecular Probes, Eugene, OR) following
the manufacturer’s instructions.
Limit of Detection
The limit of detection (LOD) of the different viruses was determined in the following manner.
First, 10-fold serial dilutions of the synthetically prepared, previously quantified, RNA tran-
scripts of LASV, RVFV, YFV, MARV and CCHFV (1x1010 to 1x100 copies/ml) were used in
the PCR reaction to determine the limit of detection. Second, the quantified VACV virus DNA
stocks obtained from BEI Resources were serially diluted in nuclease-free water and 5 μl of
each of the DNA dilutions was used in the PCR reaction to determine limit of detection. Third,
serial dilutions (ten-fold) of viral culture stocks were prepared for EBOV (Zaire ebolavirus ‘95)
Multiplex PCR/LDR Assay for VHF and Poxviruses
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from inactivated standard stock cultures. Dilutions were prepared in Dulbecco’s minimum
essential medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad,
California). RNA was extracted from 140 μl of each dilution, and RT-PCR-LDR/universal
array was used to determine the analytical sensitivity of the assay.
Fig 1. Schematic of the PCR/LDR assay for detection of VHF viruses. For each virus (ebolavirus is shown as a representative virus), 1–2 different
regions are amplified by RT-PCR using forward and reverse primers, each with minimal degeneracy and all containing universal tails to prevent the formation
of primer dimers. Cy-3 labeled downstream LDR primers and single base-discriminating upstream primers with unique zip-code complements (20-30-mers)
are targeted to specific sequences/SNPs within the PCR amplicons. Ligation of two adjacent oligonucleotides annealed to a complementary DNA target
occurs in the presence of thermostable ligase only if the nucleotides are perfectly matched at the junction [54, 55]. The zip-code complements on the 5’ end of
fluorescently labeled LDR products anneal to specific complementary zip-code addresses on a universal array [56, 57]. A positive signal on the universal
array is detected as a fluorescent spot. Primers for the ligation reaction were designed targeting 2 or 3 areas within each PCR amplicon. Each virus could
produce a maximum of six ligation products, except for VAR and VACC, for which there were a maximum of 5 each. The detection of 2 or more ligation
products was required for the detection and identification of a virus. Representative arrays that detect and identify Ebola Zaire, Lassa and Yellow fever
viruses are shown.
doi:10.1371/journal.pone.0138484.g001
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Results
Evaluation of the Assay Using Viral Strains
The PCR/LDR/universal array was validated on 53 different samples including viral culture fil-
trates, vaccine strains of viruses, nucleic acid from VACV viruses, and PCR amplicons<500bp
in size of VARV. Fig 2 depicts the ability of the primers to detect and differentiate the viruses
from each other. The PCR-LDR assay was able to detect all 32 strains, representing 9 different
viruses that were included in the assay. No signals were observed for blank no-template con-
trols and no false positives were seen with 8 other related viruses (data not shown). The assay
was designed to provide redundancy and account for sequence drift in the viruses to be
Fig 2. Comparison of universal array profile of viral RNA/DNA tested for the corresponding zip-codes.Normalized average signal intensity for the zip-
codes assigned to each virus are presented. The color bars are the signals obtained with the indicated virus (positives). The black bars are the signals
produced by the other ten viruses. A signal was considered positive if the intensity of the zip-code spot was at least 10-fold higher than the uniform
background level of fluorescence of the array slide. Although a few other viruses produced low-level positive signals for zip18, this did not result in any false
positive results since positive signals from at least two addresses was required for a positive identification. In the future, this issue would be rectified by
switching to a different zip-code. The average signal intensity for the positives ranged from 31.2 to 123.4, depending on the virus. The average signal
intensity for the negatives ranged from 0.3 to 6.2, thus they were not considered positive signals.
doi:10.1371/journal.pone.0138484.g002
Multiplex PCR/LDR Assay for VHF and Poxviruses
PLOS ONE | DOI:10.1371/journal.pone.0138484 September 18, 2015 8 / 16
examined. Two regions were targeted for PCR amplification and between 2–3 regions within
each PCR amplicon were targeted for the ligation reaction such that there were a maximum of
5 or 6 possible signals for each DNA or RNA virus respectively, but only 2 positive signals were
required to confirm the identification of any given virus. Using this criterion, the assay detected
all 11 viruses/strains with no false identification. Seven of the viruses generated positive signals
for all LDR targets (5/5 or 6/6) and three were positive at 5/6 targets (see Fig 2). We observed
only 3 positive signals in Sudan ebolavirus because only one PCR region was successfully
amplified. None of these signal drop-outs affected identification of the viral species and were
expected given the inherent variability of RNA viruses.
Due to restrictions on the possession of VARV and its nucleic acid, DNA extraction and
PCR amplification of the RAP94 and RPO147 genes was performed at the CDC. All 5 possible
LDR signals from the 8 strains representative of sequence variants in the CDC repository were
positive. The experiments were performed in accordance with the regulations and permission
of the WHO. All 5 possible signals were detected for the VACV strains tested. No false-positive
reactions were observed. The primers for VACV did not produce false signals with VARV
DNA and vice versa, nor did either set of primers interact with cowpox virus or monkeypox
virus DNA (data not shown).
Limit of Detection
The limits of detection using either synthetically transcribed RNA or dilutions of whole virus
are shown in Table 3. The LODs for CCHFV and MARV viruses were 190 and 53 RNA copies/
ml respectively. The LODs for RVFV and LASV were 7.6 and 100 RNA copies/ml, respectively.
The LODs for the whole virus dilutions tested for EBOV and DENV were 1000 FFU/ml and
1PFU/ml respectively. The calculated limits of detection per PCR reaction for EBOV and
DENV viruses were<10 copies/PCR reaction. The LOD for the DNA virus, VACV was found
to be 104 genome equivalents/reaction.
Discussion
We describe a multiplex detection assay that can simultaneously detect and differentiate 7
VHF viruses, VARV and VACV, in a single assay and is amenable to adaptation to a high-
Table 3. The limit of detection of the PCR/LDR/Universal Array assay using in vitro transcribed RNA
or whole virus.
Organism RNA detected (copies/ml) a Whole Virus detected b
MARV 1.9 x 102 ND
CCHFV 5.3x101 ND
LASV 1x102 ND
RVFV 7.6x100 ND
DENV ND 1 pfu/ml
EBOV ND 5x103 FFU/ml
YFV 5.5x100 ND
ND = Not determined
Pfu/ml = plaque forming units/ml
ffu/ml = focus forming units/ml.
a PCR/LDR was performed on cloned RNA fragments for all viruses except EBOV and DENV while
bdilutions of culture supernatants were used for the latter two viruses. Zaire ebolavirus’95 was used for
determination of LOD.
doi:10.1371/journal.pone.0138484.t003
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throughput format. The PCR/LDR/universal array was validated on 53 different samples
including viral culture filtrates, vaccine strain of viruses, serum specimens from patients with
DENV infection, nucleic acid from VACV viruses and PCR amplicons<500bp in size of
VARV. Since the viruses that cause the VHF syndrome include variant viral species with
diverse geographical distributions, we attempted to include viruses from several geographic
areas and viral species when applicable. The assay has some built-in redundancy, by including
6 possible signals for each virus (only 2 of which are required for identification), to account for
the genetic diversity often encountered in RNA viruses. We encountered signal drop-out in
some of the viral species but the assay was able to detect all viruses included in the panel. Addi-
tionally, the number of signals detected, or the fluorescent intensity of the signals generated,
was robust for all samples tested.
Early stages of infection for most of these viruses are relatively non-specific. For some
viruses, such as RFV and Lassa, the classical hemorrhagic manifestations may be absent, mak-
ing accurate and timely diagnosis challenging. A multiplexed detection assay such as the PCR/
LDR has a potential benefit in being able to screen for several pathogens in an endemic area or
in symptomatic returning travelers. In fact, there are several multiplex assays that have been
developed in the recent years to address this issue [41]. The analytical sensitivity of our assay
was comparable to recently described real-time PCR based assays [41]. The PCR/LDR has the
significant advantage of testing for 9 agents simultaneously and is amenable to automation.
Additional targets can be added to the repertoire without compromising the performance of
the assay.
The multiplex capability of PCR-LDR allowed an assay design that can distinguish viral
strains that differ in geographic distribution and virulence. There are currently five recognized
species of ebolavirus, two of which, Sudan ebolavirus and Zaire ebolavirus, have been consis-
tently recognized as causing large outbreaks since 1976 with the most recent in 2014 [11, 42].
The remaining three species, Tai Forest ebolavirus (formerly Cote d’Ivoire), Reston and Bundi-
bugyo ebolaviruses have occurred less frequently [11]. Tai Forest ebolavirus has been implicated
in a single human infection acquired during the autopsy of a wild chimpanzee [43]. Reston ebo-
lavirus causes VHF and death in primates and illness in pigs [2]. Antibody seroconversion in
human contacts of infected animals has been documented but without any associated disease.
Although Reston ebolavirus is thought to be non-pathogenic in humans, the WHO has cau-
tioned that the effect of the infection in the immunosuppressed, pregnant women, and children
is unknown [44]. Its detection therefore remains potentially clinically important. In contrast,
the relatively new Bundibugyo ebolavirus is known to be pathogenic. The outbreak in Uganda
(2007–8) resulted in 100 cases with a fatality rate of ~40% [7, 10, 42]. The PCR/LDR assay was
successful in the identification of the two major outbreak associated isolates of Zaire ebolavirus
as well as the isolates of Sudan and Reston ebolaviruses tested (Table 1). Signal dropout was
noted in Sudan ebolavirus for all three LDR products for the nucleoprotein gene. Since 2 out of
6 signals were required for positive identification, this did not affect the sensitivity of the assay.
The assay was able to detect MARV from the initial 1967 Ugandan derived German isolate
as well as the two Kenyan isolates derived from infections associated with the Kitum Cave in
Kenya’s Mount Elgon National Park in 1980 and 1987 [2, 45]. Of the CCHFV S segment-
defined groups (A, B and C) the assay was able to detect group A viruses from both the African
and Asian clades as well as group B virus. Group C was not tested but contains a single virus
isolated from a tick in Greece [46].
The assay detects all VARV genetic sequence variants in the CDC repository for the targeted
regions. Comparative genomics of 45 geographically diverse VARV isolates obtained over 30
years during the smallpox era indicate low sequence diversity [39]. Hence, we anticipate that
our assay would be capable of detecting the virus in the event of a bioterror attack. Since
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vaccination would be instituted in the event of the intentional release of variola, and vaccine
strains can be spread secondarily, the assay is also designed to detect and identify VACV vac-
cine strains. The current version of the assay does not include specific primers for the detection
of zoonotic Orthopoxviruses: monkeypox in particular [47], or the more clinically benign cow-
pox [47–49]. It was designed, however, to permit their exclusion. The modular nature of the
assay allows for the expansion of the number of organisms and targets that can be identified.
Future versions of the assay could be designed to include these viruses, and other hemorrhagic
fever viruses such as those of South America, without compromising the sensitivity and speci-
ficity of the assay.
When our assay was initially developed, the sequence information for Bundibugyo, Tai For-
est, and the 2014 Zaire ebolavirus species were unavailable in the public databases, and there-
fore their detection was not incorporated. Analysis of the Zaire ebolavirus implicated in the
2014 West African outbreak indicate that it would be detected and correctly identified by the
assay (S1 and S2 Figs). In addition, analysis of the assay PCR primers for both the NP and L
gene amplicons suggest that PCR products would be generated for both Bundibugyo and Tai
Forest ebolaviruses (S1 Fig). These analyses however would need to be verified experimentally.
Given the modular nature of the assay it would be relatively simple to add additional LDR
primers for detection of both Bundibugyo and Tai Forest ebolaviruses to our existing assay. For
example, our prototype PCR/LDR DENV assay was modified to permit the detection of an
unusual strain of DENV [37].
The assay described in this study has not yet been used to detect and identify viruses directly
from clinical materials nor was it directly compared to other available assays. However, we
have used similar PCR/LDR assays to test for DENV in 350 acute phase serum specimens and
for WNV in 142 plasma samples from blood donors. The sensitivity and specificity of the
WNV assay was 100% and that of the DENV assay was 98.7% and 98.4% respectively [37, 38].
The analytical sensitivity of the assay in its present form (7–200 copies of RNA/ml of sample
tested) is equivalent to<100 viral particles per assay. This is comparable to other techniques
used for the detection of RNA viruses [15, 24, 41, 50]. In theory, therefore, it should detect an
infection in clinical materials due to viruses in the current assay panel.
Nucleic acid extraction for this assay utilized manual extraction methods and thus required
5–6 hours. However, there are several platforms that offer high-throughput automated extrac-
tion and are in use in clinical laboratories [51, 52]. The PCR, LDR and hybridization steps have
been adapted to automation in a 96-well format on a liquid handling robot in our laboratory.
We have also used a 96-well bead-based array platform (BeadXpress, Illumina Inc. San Diego,
CA) for downstream detection of ligation products (unpublished data, [53]). The combination
of automated extraction and hybridization steps will decrease both hands-on and turn-around
time for this assay which would be critical in a high volume situation such as occurred during
the US anthrax attacks of 2001 [15]. Although the current version of the assay was not designed
for point-of-care diagnoses, adaptations currently under investigation are designed to permit
this.
PCR/LDR has a major advantage over traditional PCR based assays due to the high fidelity
of the thermostable ligase enzyme; it is highly specific for a given nucleotide sequence at the
site of ligation [54, 55]. The addition of a universal array, spotted with zip-code addresses, has
a unique potential to recognize pathogen-specific zip-code complements appended to the LDR
primers [56, 57]. This provides an additional technical advantage over existing PCR-based
assays, in that it obviates the use of actual genetic sequence on the array for pathogen detection.
This is especially useful for multiplexing, as a large number of genomic targets can be detected
simultaneously using this array. Such multiplexing capability presents the possibility that an
assay panel could be designed to target several pathogens with similar clinical features in a
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given endemic area, i.e., a “customized” chip. Additionally, the same array can be used for the
simultaneous detection of different organisms, as positive hybridization is dependent on the
chemistry of the synthesized zip-code oligonucleotides spotted on the array and their comple-
ments appended to the primers. In previous studies, we have reported the identification of 20
different bacterial species in blood cultures with a high degree of sensitivity and specificity [58].
The modular nature of this assay allows for the expansion of the number of organisms and
targets that can be identified. This is especially important for identification of potentially vari-
able genomes of viral infectious agents that may necessitate additions to the detection primers
used. Additions may also be made for the detection of new hemorrhagic fever viruses as they
emerge. The assay therefore adds a potential new tool to our armamentarium for the rapid
high throughput detection of emerging viral pathogens and potential bioterror agents.
Supporting Information
S1 Fig. PCR amplification of 2014 Zaire ebolavirus. Amplicon 1 and 2 PCR primer align-
ments of the NP and L genes of 2014 Zaire ebolavirus isolates from Guinea (KJ660348) and
Sierra Leone (KM233116), and isolates of Bundibugyo ebolavirus (NC_014373), and Tai Forest
ebolavirus (FJ217162). Zaire ebolavirus 1976 (KC242801) is included to show the original
alignment used for assay design. Nucleotides in red font indicate mismatches. Only relevant
areas of the DNA sequence with primer binding sites are shown. Numbers indicate nucleotide
positions in GenBank.
(PDF)
S2 Fig. LDR identification of 2014 Zaire ebolavirus. Amplicon 1 and 2 LDR ligation primer
alignments and ligation sites of the NP and L genes of 2014 Zaire ebolavirus isolates from
Guinea (KJ660348) and Sierra Leone (KM233116). Zaire ebolavirus 1976 (KC242801) is
included to show the original alignment used for assay design. Nucleotides in red font indicate
mismatches. Yellow indicates the single base variant at the junction ligation site. The terminal
nucleotide “T” at the 3’end highlighted in green indicates an addition to prevent quenching of
fluorescence of Cy-3 dye by the adjacent guanine bases. Only relevant areas of the DNA
sequence with primer binding sites are shown. Numbers indicate nucleotide positions in Gen-
Bank.
(PDF)
S1 Table. PCR primers used for detection of VHF and Orthopoxviruses.Multiple primers
were designed for each amplicon for the different viruses and are numbered; multiple primers
for the same virus were required to accommodate sequence variations and these are then differ-
entiated by the letters a, b, c and so forth. The underlined nucleotides indicate the sequence of
the universal tails.
(PDF)
S2 Table. LDR primers used for detection of VHF and Orthopoxviruses. Primer names indi-
cate the virus detected as well as the amplicon on which the LDR primer pairs were designed.
For example, the first primer was designed to detect RESTV and was designed on a nucleotide
position on amplicon 1. When more than one primer pair was designed for a particular virus,
they were indicated with different numbers 1,2,3 etc. When multiple primers were designed at
any LDR position an alphabetical suffix is included (for example, “A” or “B”). An amino block-
ing group (Blk) was used at the 5’end of the upstream primers and downstream primers were
labeled with Cy-3 at the 3’ end. The first 20 nucleotides of the upstream primer (underlined)
are the zip-code complements.
(PDF)
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